GRAIL shares rise as FDA panel supports cancer detection test
GRAIL (GRAL) saw its stock reach a new 52-week high after an FDA advisory panel voted in favor of the company’s multi-cancer early detection test, Galleri. The positive vote paves the way for potential U.S. approval of the blood-based screening tool. The endorsement by the FDA panel is seen as a significant milestone for GRAIL and could lead to broader adoption of its technology among healthcare providers. This development has been well-received in the market, with investors reacting positively to the regulatory progress.
Tickers: $GRAL
Topics: biotech medical testing stock movement